| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3185 |
| Trial ID | NCT05543356 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax;Pfizer Bivalent COVID-19 Vaccine|Moderna Bivalent mRNA Vaccine |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US;US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Phase | Phase3 |
| Recruitment status | Withdrawn |
| Title | A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of a Second Standard Monovalent (Ancestral) or Bivalent Omicron-specific COVID-19 Vaccine Booster Dose (Pfizer-BioNTech or Moderna) in Healthy Adults in Australia. |
| Year | 2023 |
| Country | Australia |
| Company sponsor | Murdoch Childrens Research Institute |
| Other ID(s) | 88825 |
| Vector information | |||
|
|||
| Cohort1: Tozinameran | |||||||||
|
|||||||||
| Cohort2: Elasomeran | |||||||||
|
|||||||||
| Cohort3: BNT162b2 OMI | |||||||||
|
|||||||||
| Cohort4: B.1.1.529 OMI | |||||||||
|
|||||||||